Alex Ling

Brain cancer researcher in the Mass General Brigham Neurosurgery Department

[Alex Ling @A_L_Ling]

Excited to share our latest work with the stellar GBM TeamLab at Break Through Cancer. We longitudinally sampled GBM tumors through 4 months of oHSV treatment and applied multi-omic profiling to understand the impact of the therapy over space and time. https://t.co/CTUdsC4Meg

[Alex Ling @A_L_Ling]

Oops, had to repost to fix a typo :P

[Alex Ling @A_L_Ling]

Excited to share our phase I clinical results for CAN-3110, an oncolytic HSV1, in recurrent glioma. We saw some nice immune recruitment that was associated with survival--especially in patients who had pre-existing HSV1 serology: https://t.co/9xAceJ2X61

[Nature Biotechnology @NatureBiotech]

Perturb-seq at genome scale predicts the function of poorly characterized genes. #NBThighlight https://t.co/q6AOV5VuCY

[Cancer Cell @Cancer_Cell]

Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines https://t.co/84tWhxJblX

[Alex Ling @A_L_Ling]

Our newest predictive model for drug combination efficacy, and further evidence that a significant portion of the clinical efficacy of cancer drug combinations can be explained by independent drug action. Looking forward to hearing everyone's thoughts.

[Nature Communications @NatureComms]

A computational model that can predict the efficacy of drug combinations using monotherapy data from high-throughput cancer cell line screens. #cancerresearch@huang_lab and @A_L_Ling https://t.co/Os4AeBlW6f